BR112014009785B1 - método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef) - Google Patents

método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef) Download PDF

Info

Publication number
BR112014009785B1
BR112014009785B1 BR112014009785-2A BR112014009785A BR112014009785B1 BR 112014009785 B1 BR112014009785 B1 BR 112014009785B1 BR 112014009785 A BR112014009785 A BR 112014009785A BR 112014009785 B1 BR112014009785 B1 BR 112014009785B1
Authority
BR
Brazil
Prior art keywords
collagenase
injection
area
administered
injections
Prior art date
Application number
BR112014009785-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014009785A8 (pt
BR112014009785A2 (pt
Inventor
Susan G. Emeigh Hart
Original Assignee
Auxilium International Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium International Holdings, Inc. filed Critical Auxilium International Holdings, Inc.
Publication of BR112014009785A2 publication Critical patent/BR112014009785A2/pt
Publication of BR112014009785A8 publication Critical patent/BR112014009785A8/pt
Publication of BR112014009785B1 publication Critical patent/BR112014009785B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014009785-2A 2011-10-21 2012-10-19 método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef) BR112014009785B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
US61/549,863 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Publications (3)

Publication Number Publication Date
BR112014009785A2 BR112014009785A2 (pt) 2017-04-25
BR112014009785A8 BR112014009785A8 (pt) 2020-02-27
BR112014009785B1 true BR112014009785B1 (pt) 2020-06-30

Family

ID=48141393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009785-2A BR112014009785B1 (pt) 2011-10-21 2012-10-19 método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef)

Country Status (14)

Country Link
US (2) US20140335072A1 (enExample)
EP (2) EP2768523B1 (enExample)
JP (5) JP2014530873A (enExample)
AU (6) AU2012325941A1 (enExample)
BR (1) BR112014009785B1 (enExample)
CA (1) CA2852942C (enExample)
DK (2) DK3581199T3 (enExample)
ES (2) ES2741476T3 (enExample)
FI (1) FI3581199T3 (enExample)
HU (2) HUE063599T2 (enExample)
MX (2) MX392388B (enExample)
PL (1) PL3581199T3 (enExample)
PT (2) PT3581199T (enExample)
WO (1) WO2013059619A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
EP2844276B1 (en) 2012-05-01 2019-10-02 Proteolease Ltd. Methods for extracting a tooth
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) * 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
BR112019018277A2 (pt) * 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
KR20250171475A (ko) * 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
MX2021000901A (es) * 2018-07-23 2021-06-18 Revelle Aesthetics Inc Sistema y metodos de tratamiento de celulitis.
ES2989422T3 (es) 2018-07-23 2024-11-26 Revelle Aesthetics Inc Sistema de tratamiento de celulitis
CA3112437A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
CA3153485A1 (en) 2019-09-06 2021-03-11 Revelle Aesthetics, Inc. Cellulite treatment system and methods
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
US8617543B2 (en) * 2007-02-14 2013-12-31 Yolare Pharmaceuticals, LLC Modified mutant collagenase and its use in fat melting and in scar reduction

Also Published As

Publication number Publication date
AU2022202987B2 (en) 2025-03-20
AU2020200763B2 (en) 2022-05-26
NZ722722A (en) 2019-05-31
EP3581199A1 (en) 2019-12-18
JP2022123073A (ja) 2022-08-23
HUE044650T2 (hu) 2019-11-28
HUE063599T2 (hu) 2024-01-28
DK3581199T3 (da) 2023-09-04
US20140335072A1 (en) 2014-11-13
FI3581199T3 (fi) 2023-08-18
CA2852942C (en) 2023-01-10
AU2012325941A1 (en) 2014-05-15
BR112014009785A8 (pt) 2020-02-27
JP2020158521A (ja) 2020-10-01
PL3581199T3 (pl) 2023-09-11
NZ769098A (en) 2022-03-25
DK2768523T3 (da) 2019-07-22
JP2024123126A (ja) 2024-09-10
US20240216485A1 (en) 2024-07-04
AU2020200763A1 (en) 2020-02-20
AU2016202026A1 (en) 2016-04-21
NZ624057A (en) 2016-08-26
MX392388B (es) 2025-03-24
EP2768523B1 (en) 2019-05-22
CA2852942A1 (en) 2013-04-25
AU2022202987A1 (en) 2022-05-26
WO2013059619A1 (en) 2013-04-25
AU2017248451A1 (en) 2017-11-02
NZ737403A (en) 2020-05-29
BR112014009785A2 (pt) 2017-04-25
JP2018027968A (ja) 2018-02-22
EP2768523A1 (en) 2014-08-27
MX2014004792A (es) 2015-08-14
EP3581199B1 (en) 2023-05-31
PT2768523T (pt) 2019-08-29
ES2953560T3 (es) 2023-11-14
ES2741476T3 (es) 2020-02-11
JP2014530873A (ja) 2014-11-20
AU2017248451B2 (en) 2019-11-14
MX2019007779A (es) 2019-09-04
HK1201439A1 (en) 2015-09-04
AU2025204462A1 (en) 2025-07-03
PT3581199T (pt) 2023-08-31
EP2768523A4 (en) 2015-04-22
NZ759819A (en) 2020-11-27

Similar Documents

Publication Publication Date Title
BR112014009785B1 (pt) método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef)
Cavallini et al. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers
CN105209014B (zh) 含有肉毒杆菌神经毒素的药物组合物及其应用
JP6656890B2 (ja) フィラグリン産生促進剤
CN103301064B (zh) 一种白介素-2或其衍生物鼻喷剂及其制备方法
Bunn et al. Protein and amino acid supplementation does not alter proteolytic gene expression following immobilization
HK40020065A (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
HK40020065B (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
Brimhall et al. Relative bioavailability of a single 4-mg dose of somatropin administered by subcutaneous injection or by needle-free device and coadministered with the growth hormone inhibitor octreotide acetate in healthy adult subjects
NZ769098B2 (en) Method of treating or reducing efp
NZ737403B2 (en) Method of treating or reducing efp
NZ722722B2 (en) Method of treating or reducing efp
HK1201439B (en) Method of treating or reducing efp
BR102024023628A2 (pt) Preparo combinado para uso na melhora do estado muscular
NZ759819B2 (en) Method of treating or reducing efp
TW202138002A (zh) A型肉毒桿菌毒素複合物、其配製劑和使用方法
WO2024120371A1 (zh) 肝动脉灌注治疗肝癌的方法
Shuster Anaphylaxis Seen with a Special Dye;• Cholestasis Caused by Cetirizine;• Acarbose and Lymphocytic Colitis;• Seizures Caused by Intravenous Alatrofloxacin;• Pedal Edema Caused by Olanzapine;• Disturbances in Electrolyte Homeostasis as an Adverse Effect of Gentamicin Therapy
Ansari Effect of locally delivered xanthan-based CHLO-SITE gel along with scaling and root planning on reduction of gingival pocket microbial counts

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 38/48

Ipc: A61K 8/66 (2006.01), A61K 38/48 (2006.01), A61Q 19

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2012, OBSERVADAS AS CONDICOES LEGAIS.